News – Page 892 – Endpoints News

Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD

6 years ago

With biosimilar threat under control (for now), Roche savors demand for its new drugs

6 years ago

Amarna raises €10M to push gene therapy platform into clinic; Editas Medicine, AskBio join forces

6 years ago

Cell therapy player GammaDelta spins off Adaptate to direct body's surveillance system

6 years ago

Ipsen splurges $25M on its second rare disease drug pact of the year, with more on the way

6 years ago

CSL accuses rival Pharming of participating in a scheme to rip off IP on HAE while recruiting senior R&D staffer

6 years ago

Eli Lilly’s first PhIII showdown for their $1.6B cancer drug just flopped — what now?

6 years ago

Under new leadership, Novartis' Sandoz unit breaks up with digital therapeutics outfit Pear

6 years ago

Alexion pays $930M to buy out Achillion and its promising companion drug to Soliris

6 years ago

Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding

6 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

6 years ago

Can CBD temper Parkinson's-related psychosis? UK researchers will look for answers in PhII study

6 years ago

Floating in stormy seas, RTW seeks $350M for new London-listed venture fund

6 years ago

Gilead's chief strategy exec gets a big promotion after orchestrating multibillion-dollar deals

6 years ago

Checkmate Pharmaceuticals brings two new execs on board; Takeda sheds 30 drugs, gains $200M in Acino deal

6 years ago

Gilead vet Alessandro Riva steers Glenmark's biotech spinoff on independent course

6 years ago

That big neurosciences R&D group Eli Lilly built is being dismantled, with layoffs and parts shipped home

6 years ago

Cyteir nets $40M for rad synthetic lethality platform — throwing another monkey wrench at cell repair

6 years ago

Patient experience data: Sanofi researchers call for more consistency from FDA

6 years ago

Woodford fired from flagship fund — which won't reopen after all

6 years ago

Surprising Wall Street, Reata unveils positive pivotal data on Friedreich’s ataxia drug

6 years ago

Boehringer Ingelheim-backed Abalos tosses hat into packed oncolytic virus ring

6 years ago

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

6 years ago

US mulls tariffs on Swiss drug exports, weighing on Novartis and Roche – report

6 years ago

First page Previous page 889 890 891892893 894 895 Next page Last page